governance

    fund management principles

    The Fund provides venture loans bearing interest to leading corporations active in the field - which is reflecting the high risk of the underlying portfolio - but no obligation to pay back the loan in case of failure of the respective project. 

    To mediate the investment risk, a layered fund structure has been conceived. It is composed by a public benefit investment ("First Loss Piece"), furthered by an identical amount from investors and by a donation tier ("Certain Loss Piece"). 

    The fund is managed by the Investitionsbank Berlin (IBB Group), with the European Investment Bank (EIB) participating as one of the public benefit investors. The EU Malaria Fund has been initiated by kENUP Foundation. 

    For all parties involved, the Malaria fund could also serve as a proof-of-concept for this novel private public partnership on innovation funding in domains with substantive market failures. If the fund appears to be effective and efficient, similar financing facilities may be considered, for example on antibiotics and antivirals. 

    the Scientific Advisory Council

    A Scientific Advisory Council has been established, uniting distinguished global expertise in the methods of preventive and curative intervention development:
    • Dr. Pedro Alonso*, Director of the WHO Global Malaria Programme, World Health Organization.
    • Prof. Dr. Ruth Arnon, The Paul Ehrlich Professor of Immunology, Weizmann Institute of Science. Former President of the Israel Academy of Sciences and Humanities.  
    • Prof. Dr. Stefan H. E. Kaufmann, Founding Director of the Max Planck Institute for Infection Biology Berlin. 
    • Prof. Dr. Myron Max Levine, Grollman Distinguished Professor and Associate Dean for Global Health, Vaccinology and Infectious Diseases, University of Maryland. 
    • Dr. Michael Makanga, Executive Director of the European & Developing Countries Clinical Trials Partnership (EDCTP). 
    • Dr. N. Regina Rabinovich, ExxonMobil Malaria Scholar in Residence, Harvard T.H. Chan School of Public Health, Harvard University. 
    • Stefania Salmaso, Former Director of the National Centre of Epidemiology, Surveillance and Health Promotion. Istituto Superiore di Sanità, Roma. 
    • Prof. Dr. Marcel Tanner, President of the Swiss Academy of Sciences. Chair of the Scientific Advisory Committee to the Foundation for Innovative New Diagnostics (FINDdx). Former Director of the Swiss Tropical and Public Health Institute. 
    • Prof. Dr. Halidou Tinto, Member of the Scientific Advisory Committee of EDCTP, Head of Clinical Research Unit of Nanoro (CRUN), Burkina Faso. 
    The work of the Council is supported by the following non-voting delegates to the Scientific Advisory Council
    • Jean-Luc Bodmer , the Bill & Melinda Gates Foundation. 
    • Dr. Timothy Wells, Chief Scientific Officer at Medicines for Malaria Venture (MMV). 
    • a distinguished delegate from the European Commission's Directorate-General for Research and Innovation.
    * Observer to the Scientific Advisory Council 

    governance

    The EU Malaria Fund is managed by Investitionsbank Berlin (IBB Group), the public promotional bank of the State of Berlin, a  State in the Federal Republic of Germany. The fund is domiciled in Germany. 

    Investment decisions shall made by an independent  Investment Decision Committee composed of investment professionals not related to the domain. This Fund is monitored by Investitionsbank Berlin and supervised by a Supervisory Board.  Public and private investors co-ordinate their contributions through an Investors Advisory Council. 

    The Investment Committee receives non-binding guidance from the technical and operational teams of the European Investment Bank (EIB), as well as from an expert team at the National Academy of Medicine, Washington DC - the former"IOM" - as well as from the fund's own Scientific Advisory Council. 

    The EU Malaria Fund has been initiated by kENUP Foundation. 

    processes and procedures

    In a document titled "EU Malaria Fund - Handbook of Investment Guidelines", the fund's ground rules, processes and procedures have been laid down for public review. 

    Please note that the structure, process, terms and conditions of the EU Malaria Fund presented in this handbook are preliminary and may be subject to change, depending on the decisions of various committees, as well as the administrative decisions of the stakeholders involved. Some stakeholders have been anonymised in order not to pre-empt administrative proceedings. This preliminary version of the handbook depicts a best-case working scenario, provides early guidance to interested parties, and aims at informing the further process for all stakeholders of the EU Malaria Fund.

    The draft document (currently v1.6, dated 3-Jun-2020) can be downloaded here. Your comments are most welcome under contact@controlmalaria.eu. 

    donors

    Donors and impact investors to the fund provide policy guidance to the Scientific Advisory Council through a dedicated Investor's Advisory Council. 

    the management company

    The EU Malaria Fund is managed by IBB Group, the public promotional bank of the Federal State of Berlin. General Partner of the EU Malaria is EMM EU Malaria Fund Berlin Managementgesellschaft mbH. The company's offices are located on the premises of Investitionsbank Berlin at Bundesallee 210, D-10719 Berlin, Germany. The EU Malaria Fund is managed by  Mr. Torsten Harr and Mr. Holm Keller, both acting as Managing Directors. You can reach the team at team@controlMalaria.eu.  

    the team

    Im addition to a staff of twelve at the Fund's management company, colleagues from kENUP Foundation, the European Union. the European Investment Bank, the State of Berlin, Investitionsbank  Berlin as well as from the other investors and donors are contributing to the proceedings of the EU Malaria Fund. 
    Share by: